Emerging data suggest Retatru tide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may provide a promising advancement for weight management . Early human tests have indicated considerable losses in body tissue, conceivably outperforming other body composition therapies . Nevertheless , more assessment is